1
|
Wang J, Li X, Yuan C, Su F, Wu YB, Lu L, Zhu M, Xing S, Fu X. Syntheses, crystal structures, and biological evaluations of new dinuclear platinum(ii) complexes with 1,2,4-triazole derivatives as bridging ligands. Dalton Trans 2021; 50:4527-4538. [PMID: 33725030 DOI: 10.1039/d0dt03285a] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
A series of new dinuclear platinum(ii) complexes with the general formula [Pt2(μ-HL)4] (1-4), where H2L is 4-[(5-chloro-2-hydroxy-benzylidene)-amino]-3-R-1,2,4-triazole-5-thione: R = H (1), methyl (2), ethyl (3) and propyl (4), were synthesized and characterized. The X-ray crystal structures of 2, 3 and 4 reveal that the two platinum atoms form a paddlewheel core with four chelating triazole ligands as bridges, revealing a radically different structure than those of the traditional anticancer platinum(ii) complexes. These complexes show higher in vitro antiproliferative activity against human liver hepatocellular carcinoma (HepG2) and human breast adenocarcinoma (MCF7) than human lung cancer (A549) and human normal hepatocyte (HL-7702) cell lines. In particular, 3 exhibits antiproliferative activity (IC50 = 5.5 μM) against HepG2 cells comparable to that of cisplatin. Different from the traditional anticancer platinum(ii) complexes with high DNA affinity, 3 binds very weakly to DNA. Upon comparison, it exhibits potent inhibiting activity against protein tyrosine phosphatases 1B (PTP1B, IC50 = 16 μM) through possible binding to its active sites and its binding constant is 5.28 × 104 M-1. The results suggest that the antiproliferative mechanism of 3 against HepG2 cells may be different from that of cisplatin.
Collapse
Affiliation(s)
- Jianwei Wang
- Key Laboratory of Materials for Energy Conversion and Storage of Shanxi Province, Key Laboratory of Chemical Biology and Molecular Engineering of the Education Ministry, Institute of Molecular Science, Shanxi University, Taiyuan, 030006, Shanxi, P. R. China.
| | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Hreusová M, Nováková O, Kostrhunová H, Prachařová J, Brabec V, Kašpárková J. DNA modification by cisplatin-like Pt(II) complexes containing 1,1′-binaphtyl-2,2′-diamine ligand does not correlate with their antiproliferative activity in cancer cells. Inorganica Chim Acta 2019. [DOI: 10.1016/j.ica.2019.06.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
3
|
Komeda S, In Y, Tomoo K, Minoura K, Sato T, Reedijk J, Ishida T, Chikuma M. Associative intraligand substitution of anticancer azolato-bridged compounds without a square-pyramidal intermediate: Formation of a unique tetranuclear, µ3-1,2,3-triazolato-N1,N2,N3-bridged Pt(II) compound. Inorganica Chim Acta 2019. [DOI: 10.1016/j.ica.2019.118999] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
4
|
In Vitro Cytotoxicity and In Vivo Antitumor Efficacy of Tetrazolato-Bridged Dinuclear Platinum(II) Complexes with a Bulky Substituent at Tetrazole C5. INORGANICS 2019. [DOI: 10.3390/inorganics7010005] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Tetrazolato-bridged dinuclear platinum(II) complexes ([{cis-Pt(NH3)2}2(μ-OH)(μ-5-R-tetrazolato-N2,N3)]2+; tetrazolato-bridged complexes) are a promising source of next-generation platinum-based drugs. β-Cyclodextrin (β-CD) forms inclusion complexes with bulky organic compounds or substituents, changing their polarity and molecular dimensions. Here, we determined by 1H-NMR spectroscopy, the stability constants for inclusion complexes formed between β-CD and tetrazolato-bridged complexes with a bulky, lipophilic substituent at tetrazole C5 (complexes 1–3, phenyl, n-nonyl, and adamantyl substitution, respectively). We then determined the in vitro cytotoxicity and in vivo antitumor efficacy of complexes 1–3 against the Colon-26 colorectal cancer cell line in the absence or presence of equimolar β-CD. Compared with the platinum-based anticancer drug oxaliplatin (1R,2R-diaminocyclohexane)oxalatoplatinum(II)), complex 2 had similar cytotoxicity, complex 3 was moderately cytotoxic, and complex 1 was the least cytotoxic. The cytotoxicity of the complexes decreased in the presence of β-CD. When we examined the in vivo antitumor efficacy of complexes 1–3 (10 mg/kg) against homografted Colon-26 colorectal tumors in male BALB/c mice, they showed a relatively low tumor growth inhibition compared with oxaliplatin. However, in the presence of β-CD, complex 3 had higher in vivo antitumor efficacy than oxaliplatin, suggesting a new direction for future research into tetrazolato-bridged complexes with high in vivo antitumor activity.
Collapse
|
5
|
Komeda S, Yoneyama H, Uemura M, Tsuchiya T, Hoshiyama M, Sakazaki T, Hiramoto K, Harusawa S. Synthesis and structure-activity relationships of tetrazolato-bridged dinuclear platinum(II) complexes: A small modification at tetrazole C5 markedly influences the in vivo antitumor efficacy. J Inorg Biochem 2019; 192:82-86. [PMID: 30612029 DOI: 10.1016/j.jinorgbio.2018.12.009] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2018] [Revised: 12/17/2018] [Accepted: 12/21/2018] [Indexed: 02/04/2023]
Abstract
We synthesized and characterized 15 new derivatives of the highly anticancer-active platinum(II) complex [{cis-Pt(NH3)2}2(μ-OH)(μ-tetrazolato-N2,N3)]2+ (5-H-Y) by making substitutions at tetrazole C5. We then evaluated the comprehensive structure-cytotoxicity relationships of a total of 23 derivatives in two murine lymphocytic leukaemia cell lines, sensitive and resistant to cisplatin. We also report the in vivo antitumor efficacy of three ester derivatives, two of which exhibited much higher efficacy than oxaliplatin against mouse homografted Colon-26 colorectal tumor.
Collapse
Affiliation(s)
- Seiji Komeda
- Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka 513-8670, Japan.
| | - Hiroki Yoneyama
- Department of Pharmaceutical Organic Chemistry, Osaka University of Pharmaceutical Sciences, 4-20-1 Nasahara, Takatsuki, Osaka 569-1094, Japan
| | - Masako Uemura
- Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka 513-8670, Japan
| | - Takahiro Tsuchiya
- Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka 513-8670, Japan
| | - Miyuu Hoshiyama
- Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka 513-8670, Japan
| | - Tomoya Sakazaki
- Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka 513-8670, Japan
| | - Keiichi Hiramoto
- Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka 513-8670, Japan
| | - Shinya Harusawa
- Department of Pharmaceutical Organic Chemistry, Osaka University of Pharmaceutical Sciences, 4-20-1 Nasahara, Takatsuki, Osaka 569-1094, Japan.
| |
Collapse
|
6
|
Rehm T, Rothemund M, Bär A, Dietel T, Kempe R, Kostrhunova H, Brabec V, Kasparkova J, Schobert R. N,N-Dialkylbenzimidazol-2-ylidene platinum complexes – effects of alkyl residues and ancillary cis-ligands on anticancer activity. Dalton Trans 2018; 47:17367-17381. [DOI: 10.1039/c8dt03360a] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Benzimidazol-2-ylidene platinum complexes exhibit anticancer activity, which is tuneable via N-alkyl residues and ancillary ligands and is different from that of cisplatin.
Collapse
Affiliation(s)
- Tobias Rehm
- Department of Chemistry
- University Bayreuth
- 95440 Bayreuth
- Germany
| | | | - Alexander Bär
- Department of Chemistry
- University Bayreuth
- 95440 Bayreuth
- Germany
| | - Thomas Dietel
- Lehrstuhl fuer Anorganische Chemie II
- University Bayreuth
- 95440 Bayreuth
- Germany
| | - Rhett Kempe
- Lehrstuhl fuer Anorganische Chemie II
- University Bayreuth
- 95440 Bayreuth
- Germany
| | - Hana Kostrhunova
- Institute of Biophysics
- Academy of Sciences of the Czech Republic
- CZ-61265 Brno
- Czech Republic
| | - Viktor Brabec
- Institute of Biophysics
- Academy of Sciences of the Czech Republic
- CZ-61265 Brno
- Czech Republic
| | - Jana Kasparkova
- Institute of Biophysics
- Academy of Sciences of the Czech Republic
- CZ-61265 Brno
- Czech Republic
| | - Rainer Schobert
- Department of Chemistry
- University Bayreuth
- 95440 Bayreuth
- Germany
| |
Collapse
|
7
|
Brabec V, Hrabina O, Kasparkova J. Cytotoxic platinum coordination compounds. DNA binding agents. Coord Chem Rev 2017. [DOI: 10.1016/j.ccr.2017.04.013] [Citation(s) in RCA: 77] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
|
8
|
Komeda S, Yoneyama H, Uemura M, Muramatsu A, Okamoto N, Konishi H, Takahashi H, Takagi A, Fukuda W, Imanaka T, Kanbe T, Harusawa S, Yoshikawa Y, Yoshikawa K. Specific Conformational Change in Giant DNA Caused by Anticancer Tetrazolato-Bridged Dinuclear Platinum(II) Complexes: Middle-Length Alkyl Substituents Exhibit Minimum Effect. Inorg Chem 2017; 56:802-811. [PMID: 28045514 DOI: 10.1021/acs.inorgchem.6b02239] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
Derivatives of the highly antitumor-active compound [{cis-Pt(NH3)2}2(μ-OH)(μ-tetrazolato-N2,N3)]2+ (5-H-Y), which is a tetrazolato-bridged dinuclear platinum(II) complex, were prepared by substituting a linear alkyl chain moiety at C5 of the tetrazolate ring. The general formula for the derivatives is [{cis-Pt(NH3)2}2(μ-OH)(μ-5-R-tetrazolato-N2,N3)]2+, where R is (CH2)nCH3 and n = 0 to 8 (complexes 1-9). The cytotoxicity of complexes 1-4 in NCI-H460 human non-small-cell lung cancer cells decreased with increasing alkyl chain length, and those of complexes 5-9 increased with increasing alkyl chain length. That is, the in vitro cytotoxicity of complexes 1-9 was found to have a U-shaped association with alkyl chain length. This U-shaped association is attributable to the degree of intracellular accumulation. Although circular dichroism spectroscopic measurement indicated that complexes 1-9 induced comparable conformational changes in the secondary structure of DNA, the tetrazolato-bridged complexes induced different degrees of DNA compaction as revealed by a single DNA measurement with fluorescence microsopy, which also had a U-shaped association with alkyl chain length that matched the association observed for cytotoxicity. Complexes 7-9, which had alkyl chains long enough to confer surfactant-like properties to the complex, induced DNA compaction 20 or 1000 times more efficiently than 5-H-Y or spermidine. A single DNA measurement with transmission electron microscopy revealed that complex 8 formed large spherical self-assembled structures that induced DNA compaction with extremely high efficiency. This result suggests that these structures may play a role in the DNA compaction that was induced by the complexes with the longer alkyl chains. The derivatization with a linear alkyl chain produced a series of complexes with unique cellular accumulation and DNA conformational change profiles and a potentially useful means of developing next-generation platinum-based anticancer drugs. In addition, the markedly high ability of these complexes to induce DNA compaction and their high intracellular accumulation emphasized the difference in mechanism of action from platinum-based anticancer drugs.
Collapse
Affiliation(s)
- Seiji Komeda
- Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science , Suzuka, Mie 513-8670, Japan
| | - Hiroki Yoneyama
- Faculty of Pharmaceutical Sciences, Osaka University of Pharmaceutical Sciences , Takatsuki, Osaka 569-1094, Japan
| | - Masako Uemura
- Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science , Suzuka, Mie 513-8670, Japan
| | - Akira Muramatsu
- Faculty of Life and Medical Sciences, Doshisha University , Kyotanabe, Kyoto 610-0394, Japan
| | - Naoto Okamoto
- Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science , Suzuka, Mie 513-8670, Japan
| | - Hiroaki Konishi
- Yakult Central Institute , Yakult Honsha Co., Ltd., Kunitachi, Tokyo 186-8650, Japan
| | - Hiroyuki Takahashi
- Pharmaceutical Research and Development Department, Yakult Honsha Co., Ltd. , Chuo, Tokyo 104-0061, Japan
| | - Akimitsu Takagi
- Yakult Central Institute , Yakult Honsha Co., Ltd., Kunitachi, Tokyo 186-8650, Japan
| | - Wakao Fukuda
- Department of Biotechnology, College of Life Sciences, Ritsumeikan University , Kusatsu, Shiga 525-8577, Japan
| | - Tadayuki Imanaka
- Department of Biotechnology, College of Life Sciences, Ritsumeikan University , Kusatsu, Shiga 525-8577, Japan
| | - Toshio Kanbe
- Laboratory of Medical Mycology, Research Institute for Disease Mechanism and Control, School of Medicine, Nagoya University , Nagoya 464-0064, Japan
| | - Shinya Harusawa
- Faculty of Pharmaceutical Sciences, Osaka University of Pharmaceutical Sciences , Takatsuki, Osaka 569-1094, Japan
| | - Yuko Yoshikawa
- Faculty of Life and Medical Sciences, Doshisha University , Kyotanabe, Kyoto 610-0394, Japan
| | - Kenichi Yoshikawa
- Faculty of Life and Medical Sciences, Doshisha University , Kyotanabe, Kyoto 610-0394, Japan
| |
Collapse
|
9
|
Johnson BW, Murray V, Temple MD. Characterisation of the DNA sequence specificity, cellular toxicity and cross-linking properties of novel bispyridine-based dinuclear platinum complexes. BMC Cancer 2016; 16:333. [PMID: 27225032 PMCID: PMC4880875 DOI: 10.1186/s12885-016-2368-0] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2015] [Accepted: 05/18/2016] [Indexed: 12/21/2022] Open
Abstract
Background The anti-tumour activity of cisplatin is thought to be a result of its capacity to form DNA adducts which prevent cellular processes such as DNA replication and transcription. These DNA adducts can effectively induce cancer cell death, however, there are a range of clinical side effects and drug resistance issues associated with its use. In this study, the biological properties of three novel dinuclear platinum-based compounds (that contain alkane bridging linkers of eight, ten and twelve carbon atoms in length) were characterised to assess their potential as anticancer agents. Methods The properties of these compounds were determined using a DNA template containing seven tandem telomeric repeat sequences. A linear amplification reaction was used in combination with capillary electrophoresis to quantify the sequence specificity of DNA adducts formed by these compounds at base pair resolution. The DNA cross-linking ability of these compounds was assessed using denaturing agarose gel electrophoresis and cytotoxicity was determined in HeLa cells using a colorimetric cell viability assay. Results The dinuclear compounds were found to preferentially form DNA adducts at guanine bases and they exhibited different damage intensity profiles at the telomeric repeat sequences compared to that of cisplatin. The dinuclear compounds were found to exhibit a low level of cytotoxicity relative to cisplatin and their cytotoxicity increased as the linker length increased. Conversely, the interstrand cross-linking efficiency of the dinuclear compounds increased as the linker length decreased and the compound with the shortest alkane linker was six-fold more effective than cisplatin. Conclusions Since the bifunctional compounds exhibit variation in sequence specificity of adduct formation and a greater ability to cross-link DNA relative to cisplatin they warrant further investigation towards the goal of developing new cancer chemotherapeutic agents.
Collapse
Affiliation(s)
- Ben W Johnson
- School of Science and Health, Western Sydney University, Campbelltown, NSW, 2560, Australia
| | - Vincent Murray
- School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW, 2052, Australia
| | - Mark D Temple
- School of Science and Health, Western Sydney University, Campbelltown, NSW, 2560, Australia.
| |
Collapse
|
10
|
Imai R, Komeda S, Shimura M, Tamura S, Matsuyama S, Nishimura K, Rogge R, Matsunaga A, Hiratani I, Takata H, Uemura M, Iida Y, Yoshikawa Y, Hansen JC, Yamauchi K, Kanemaki MT, Maeshima K. Chromatin folding and DNA replication inhibition mediated by a highly antitumor-active tetrazolato-bridged dinuclear platinum(II) complex. Sci Rep 2016; 6:24712. [PMID: 27094881 PMCID: PMC4837362 DOI: 10.1038/srep24712] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2015] [Accepted: 04/05/2016] [Indexed: 11/13/2022] Open
Abstract
Chromatin DNA must be read out for various cellular functions, and copied for the next cell division. These processes are targets of many anticancer agents. Platinum-based drugs, such as cisplatin, have been used extensively in cancer chemotherapy. The drug–DNA interaction causes DNA crosslinks and subsequent cytotoxicity. Recently, it was reported that an azolato-bridged dinuclear platinum(II) complex, 5-H-Y, exhibits a different anticancer spectrum from cisplatin. Here, using an interdisciplinary approach, we reveal that the cytotoxic mechanism of 5-H-Y is distinct from that of cisplatin. 5-H-Y inhibits DNA replication and also RNA transcription, arresting cells in the S/G2 phase, and are effective against cisplatin-resistant cancer cells. Moreover, it causes much less DNA crosslinking than cisplatin, and induces chromatin folding. 5-H-Y will expand the clinical applications for the treatment of chemotherapy-insensitive cancers.
Collapse
Affiliation(s)
- Ryosuke Imai
- Biological Macromolecules Laboratory, Structural Biology Center, National Institute of Genetics, Mishima, Shizuoka 411-8540, Japan.,Department of Genetics, School of Life Science, Sokendai (Graduate University for Advanced Studies), Mishima, Shizuoka 411-8540, Japan
| | - Seiji Komeda
- Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka, Mie, 513-8670
| | - Mari Shimura
- CREST, JST, 4-1-8 Honcho, Kawaguchi, Saitama 332-0012, Japan.,Department of Intractable Diseases, Research Institute, National Center for Global Health and Medicine, Shinjuku, Tokyo 162-8655, Japan.,RIKEN SPring-8 Center, 1-1-1 Kouto, Sayo-cho, Sayo-gun, Hyogo 679-5148, Japan
| | - Sachiko Tamura
- Biological Macromolecules Laboratory, Structural Biology Center, National Institute of Genetics, Mishima, Shizuoka 411-8540, Japan.,CREST, JST, 4-1-8 Honcho, Kawaguchi, Saitama 332-0012, Japan
| | - Satoshi Matsuyama
- CREST, JST, 4-1-8 Honcho, Kawaguchi, Saitama 332-0012, Japan.,RIKEN SPring-8 Center, 1-1-1 Kouto, Sayo-cho, Sayo-gun, Hyogo 679-5148, Japan.,Department of Precision Science &Technology, Graduate School of Engineering, Osaka University, 2-1 Yamada-oka Suita, Osaka, Japan 565-0871
| | - Kohei Nishimura
- Center for Frontier Research, National Institute of Genetics, Yata 1111, Mishima, Shizuoka 411-8540, Japan
| | - Ryan Rogge
- Department of Biochemistry and Molecular Biology, Colorado State University, Fort Collins, CO 80523, USA
| | - Akihiro Matsunaga
- CREST, JST, 4-1-8 Honcho, Kawaguchi, Saitama 332-0012, Japan.,Department of Intractable Diseases, Research Institute, National Center for Global Health and Medicine, Shinjuku, Tokyo 162-8655, Japan.,RIKEN SPring-8 Center, 1-1-1 Kouto, Sayo-cho, Sayo-gun, Hyogo 679-5148, Japan
| | - Ichiro Hiratani
- Biological Macromolecules Laboratory, Structural Biology Center, National Institute of Genetics, Mishima, Shizuoka 411-8540, Japan.,Department of Genetics, School of Life Science, Sokendai (Graduate University for Advanced Studies), Mishima, Shizuoka 411-8540, Japan.,Laboratory for Developmental Epigenetics, RIKEN Center for Developmental Biology, Kobe 650-0047, Japan
| | - Hideaki Takata
- Biological Macromolecules Laboratory, Structural Biology Center, National Institute of Genetics, Mishima, Shizuoka 411-8540, Japan.,Frontier Research Base for Global Young Researchers, Graduate School of Engineering Osaka University, 2-1 Yamada-oka, Suita, Osaka 565-0871, Japan
| | - Masako Uemura
- Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka, Mie, 513-8670
| | - Yutaka Iida
- Inorganic Analysis Laboratories, Toray Research Center, Inc., 3-3-7, Sonoyama, Otsu, Shiga 520-8567, Japan
| | - Yuko Yoshikawa
- Research Organization of Science and Engineering, Ritsumeikan University, Kusatsu, Shiga 525-8577, Japan
| | - Jeffrey C Hansen
- Department of Biochemistry and Molecular Biology, Colorado State University, Fort Collins, CO 80523, USA
| | - Kazuto Yamauchi
- CREST, JST, 4-1-8 Honcho, Kawaguchi, Saitama 332-0012, Japan.,RIKEN SPring-8 Center, 1-1-1 Kouto, Sayo-cho, Sayo-gun, Hyogo 679-5148, Japan.,Department of Precision Science &Technology, Graduate School of Engineering, Osaka University, 2-1 Yamada-oka Suita, Osaka, Japan 565-0871
| | - Masato T Kanemaki
- Department of Genetics, School of Life Science, Sokendai (Graduate University for Advanced Studies), Mishima, Shizuoka 411-8540, Japan.,Center for Frontier Research, National Institute of Genetics, Yata 1111, Mishima, Shizuoka 411-8540, Japan.,PRESTO, JST, 4-1-8 Honcho, Kawaguchi, Saitama 332-0012, Japan
| | - Kazuhiro Maeshima
- Biological Macromolecules Laboratory, Structural Biology Center, National Institute of Genetics, Mishima, Shizuoka 411-8540, Japan.,Department of Genetics, School of Life Science, Sokendai (Graduate University for Advanced Studies), Mishima, Shizuoka 411-8540, Japan.,CREST, JST, 4-1-8 Honcho, Kawaguchi, Saitama 332-0012, Japan.,RIKEN SPring-8 Center, 1-1-1 Kouto, Sayo-cho, Sayo-gun, Hyogo 679-5148, Japan
| |
Collapse
|
11
|
Platinum-based drugs: past, present and future. Cancer Chemother Pharmacol 2016; 77:1103-24. [PMID: 26886018 DOI: 10.1007/s00280-016-2976-z] [Citation(s) in RCA: 541] [Impact Index Per Article: 67.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2015] [Accepted: 01/20/2016] [Indexed: 12/22/2022]
Abstract
Platinum-based drugs cisplatin, carboplatin and oxaliplatin are widely used in the therapy of human neoplasms. Their clinical success is, however, limited due to severe side effects and intrinsic or acquired resistance to the treatment. Much effort has been put into the development of new platinum anticancer complexes, but none of them has reached worldwide clinical application so far. Nedaplatin, lobaplatin and heptaplatin received only regional approval. Some new platinum complexes and platinum drug formulations are undergoing clinical trials. Here, we review the main classes of new platinum drug candidates, such as sterically hindered complexes, monofunctional platinum drugs, complexes with biologically active ligands, trans-configured and polynuclear platinum complexes, platinum(IV) prodrugs and platinum-based drug delivery systems. For each class of compounds, a detailed overview of the mechanism of action is given, the cytotoxicity is compared to that of the clinically used platinum drugs, and the clinical perspectives are discussed. A critical analysis of lessons to be learned is presented. Finally, a general outlook regarding future directions in the field of new platinum drugs is given.
Collapse
|
12
|
Medici S, Peana M, Nurchi VM, Lachowicz JI, Crisponi G, Zoroddu MA. Noble metals in medicine: Latest advances. Coord Chem Rev 2015. [DOI: 10.1016/j.ccr.2014.08.002] [Citation(s) in RCA: 373] [Impact Index Per Article: 41.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
|
13
|
Uemura M, Hoshiyama M, Furukawa A, Sato T, Higuchi Y, Komeda S. Highly efficient uptake into cisplatin-resistant cells and the isomerization upon coordinative DNA binding of anticancer tetrazolato-bridged dinuclear platinum(ii) complexes. Metallomics 2015; 7:1488-96. [DOI: 10.1039/c5mt00174a] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
14
|
Pages BJ, Ang DL, Wright EP, Aldrich-Wright JR. Metal complex interactions with DNA. Dalton Trans 2015; 44:3505-26. [DOI: 10.1039/c4dt02700k] [Citation(s) in RCA: 241] [Impact Index Per Article: 26.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Increasing numbers of DNA structures are being revealed using a diverse range of transition metal complexes and biophysical spectroscopic techniques. Here we present a review of metal complex-DNA interactions in which several binding modes and DNA structural forms are explored.
Collapse
Affiliation(s)
- Benjamin J. Pages
- Nanoscale Organisation and Dynamics Group
- School of Science and Health
- University of Western Sydney
- Locked Bag 1797 Penrith South DC
- Australia
| | - Dale L. Ang
- Nanoscale Organisation and Dynamics Group
- School of Science and Health
- University of Western Sydney
- Locked Bag 1797 Penrith South DC
- Australia
| | - Elisé P. Wright
- School of Medicine
- University of Western Sydney
- Locked Bag 1797 Penrith South DC
- Australia
| | - Janice R. Aldrich-Wright
- Nanoscale Organisation and Dynamics Group
- School of Science and Health
- University of Western Sydney
- Locked Bag 1797 Penrith South DC
- Australia
| |
Collapse
|
15
|
Li J, Hu X, Liu M, Hou J, Xie Z, Huang Y, Jing X. Complex of cisplatin with biocompatible poly(ethylene glycol) with pendant carboxyl groups for the effective treatment of liver cancer. J Appl Polym Sci 2014. [DOI: 10.1002/app.40764] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Affiliation(s)
- Jing Li
- State Key Laboratory of Polymer Physics and Chemistry; Changchun Institute of Applied Chemistry, Chinese Academy of Sciences; Changchun 130022 People's Republic of China
| | - Xiuli Hu
- State Key Laboratory of Polymer Physics and Chemistry; Changchun Institute of Applied Chemistry, Chinese Academy of Sciences; Changchun 130022 People's Republic of China
| | - Ming Liu
- State Key Laboratory of Polymer Physics and Chemistry; Changchun Institute of Applied Chemistry, Chinese Academy of Sciences; Changchun 130022 People's Republic of China
| | - Jie Hou
- The First Hospital of Jiamusi University; Jiamusi 154002 People's Republic of China
| | - Zhigang Xie
- State Key Laboratory of Polymer Physics and Chemistry; Changchun Institute of Applied Chemistry, Chinese Academy of Sciences; Changchun 130022 People's Republic of China
| | - Yubin Huang
- State Key Laboratory of Polymer Physics and Chemistry; Changchun Institute of Applied Chemistry, Chinese Academy of Sciences; Changchun 130022 People's Republic of China
| | - Xiabin Jing
- State Key Laboratory of Polymer Physics and Chemistry; Changchun Institute of Applied Chemistry, Chinese Academy of Sciences; Changchun 130022 People's Republic of China
| |
Collapse
|
16
|
Bologna G, Lanuti P, D'Ambrosio P, Tonucci L, Pierdomenico L, D'Emilio C, Celli N, Marchisio M, d'Alessandro N, Santavenere E, Bressan M, Miscia S. Water-soluble platinum phthalocyanines as potential antitumor agents. Biometals 2014; 27:575-89. [PMID: 24699848 DOI: 10.1007/s10534-014-9730-y] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2013] [Accepted: 03/17/2014] [Indexed: 12/14/2022]
Abstract
Breast cancer represents the second cause of death in the European female population. The lack of specific therapies together with its high invasive potential are the major problems associated to such a tumor. In the last three decades platinum-based drugs have been considered essential constituents of many therapeutic strategies, even though with side effects and frequent generation of drug resistance. These drugs have been the guide for the research, in last years, of novel platinum and ruthenium based compounds, able to overcome these limitations. In this work, ruthenium and platinum based phthalocyanines were synthesized through conventional techniques and their antiproliferative and/or cytotoxic actions were tested. Normal mammary gland (MCF10A) and several models of mammarian carcinoma at different degrees of invasiveness (BT474, MCF-7 and MDA-MB-231) were used. Cells were treated with different concentrations (5-100 μM) of the above reported compounds, to evaluate toxic concentration and to underline possible dose-response effects. The study included growth curves made by trypan blue exclusion test and scratch assay to study cellular motility and its possible negative modulation by phthalocyanine. Moreover, we investigated cell cycle and apoptosis through flow cytometry and AMNIS Image Stream cytometer. Among all the tested drugs, tetrasulfonated phthalocyanine of platinum resulted to be the molecule with the best cytostatic action on neoplastic cell lines at the concentration of 30 μM. Interestingly, platinum tetrasulfophtalocyanine, at low doses, had no antiproliferative effects on normal cells. Therefore, such platinum complex, appears to be a promising drug for mammarian carcinoma treatment.
Collapse
Affiliation(s)
- Giuseppina Bologna
- Department of Medicine and Aging Science, School of Medicine and Health Sciences, University "G. d'Annunzio" of Chieti-Pescara, Via dei Vestini, 31, 66013, Chieti Scalo, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Komeda S, Takayama H, Suzuki T, Odani A, Yamori T, Chikuma M. Synthesis of antitumor azolato-bridged dinuclear platinum(ii) complexes with in vivo antitumor efficacy and unique in vitro cytotoxicity profiles. Metallomics 2013; 5:461-8. [DOI: 10.1039/c3mt00040k] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
18
|
Olivova R, Stepankova J, Muchova T, Novohradsky V, Novakova O, Vrana O, Kasparkova J, Brabec V. Mechanistic insights into toxic effects of a benzotriazolate-bridged dinuclear platinum(II) compound in tumor cells. Inorganica Chim Acta 2012. [DOI: 10.1016/j.ica.2012.06.002] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|